1.23
-0.05(-3.91%)
Currency In NOK
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
36
First IPO Date
December 13, 2017
| Name | Title | Pay | Year Born |
| Mr. Olav Hellebo BBA, MBA | Chief Executive Officer | 0 | 1965 |
| Mr. Rune Skeie | Chief Financial Officer | 2.68M | 1973 |
| Ms. Cristina Oliva M.D. | Chief Medical Officer | 5.28M | N/A |
| Ms. Gayle M. Mills M.B.A | Chief Business Officer | 0 | 1955 |
| Graham Morell | Head of IR | 0 | N/A |
| Dr. Akil Jackson | Medical Director | 0 | N/A |
Oncoinvent ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.